Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

BARCELONA, Spain--(BUSINESS WIRE)--Apr 14, 2007 - In a late-breaker presentation at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL), researchers today presented data from a planned interim analysis of the PROVE 1 clinical trial, which is the first trial to evaluate short-duration therapy with the investigational hepatitis C protease inhibitor telaprevir (TVR, VX-950) in combination with pegylated interferon (peg-IFN) and ribavirin (RBV) in treatment-naive, genotype 1-infected hepatitis C patients. The data from PROVE 1 demonstrated a high rate of rapid viral response (RVR) in the telaprevir groups and a low rate of on-treatment viral breakthrough, and suggested that 12 weeks of telaprevir-based therapy enabled some patients to clear the virus. Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is developing telaprevir in collaboration with Tibotec.

"The high rates of RVR observed in the telaprevir groups in PROVE 1, and the fact that some patients have remained persistently viral negative 20 weeks after stopping the 12 weeks of telaprevir-based therapy, suggest that we may be able to shorten the treatment duration in genotype 1 HCV patients," said John McHutchison, M.D., Principal Investigator for the PROVE 1 study and Director of Gastroenterology and Hepatology Research at Duke Clinical Research Institute. "These interim results are encouraging and suggest that high sustained viral response (SVR) rates may be achieved with regimens that are 24 weeks in total duration. We look forward to 24 week follow-up data from the initial group of patients who stopped treatment at 12 weeks, and follow-up data from patients in the study who received 24 weeks of treatment."

PROVE 1 Summary

-- 88% and 79% of patients receiving telaprevir achieved a rapid viral response (RVR) as measured by plasma HCV RNA (less than)30 IU/mL and (less than)10 IU/mL, respectively, at 4 weeks.<
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:8/27/2015)... Mass. , Aug. 27, 2015  A ... the KSSTA Knee Journal, compared the Arthrosurface HemiCAP® ... Arthroplasty design, versus an "onlay" design implant for ... similar improvements in function and pain scores, none ... progression of osteoarthritis (OA). However, 53% of the ...
(Date:8/27/2015)... , Aug. 27, 2015 Biosimilars ... (BPC) applauds the U.S. Food and Drug Administration ... distinguishable name in its draft guidance issued today. ... biological products proposes distinguishable names, calling for biological ... an FDA-designated suffix. This proposal reflects the agency,s ...
(Date:8/27/2015)... 2015 According to a new market research ... Universal, Standing, Bariatric ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, ... by MarketsandMarkets, the Medical Lifting Sling Market is poised to reach ... at a CAGR of 11.4 % from 2015 to 2020. ... rket data T ables and 65 ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
(Date:8/28/2015)... ... , ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with ... pain, hip pain, neck pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan ... then went on to earn his title of Doctor of Chiropractic from the Palmer ...
(Date:8/28/2015)... ... August 28, 2015 , ... Northridge dentists ... teeth whitening. For just $199, patients can currently receive a one hour treatment of ... whitening procedures, but it includes a number of unique features that can turn teeth ...
(Date:8/28/2015)... ... 28, 2015 , ... Healthpointe clinics throughout Southern California ... diving. The act of recreational diving exposes the body to extreme changes ... vital that all recreational and professional divers undergo regular comprehensive scuba physicals. Healthpointe’s ...
(Date:8/28/2015)... , ... August 28, 2015 ... ... Inc.’s (AIS) Medicare-Medicaid Dual Eligibles Database have added comprehensive information on two ... demonstration approved for a December 2015 launch; and Idaho’s partnership to revamp ...
(Date:8/28/2015)... ... 2015 , ... External Counterpulsation, also known as ECP or EECP, is a ... (EECP or ECP) machines with a full clinic licence to help people prevent and ... helping people prevent and reverse heart disease through its evidence-based integrative approach ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2
... , , , ... through Delivery-system Reforms , , WASHINGTON, ... brought together several health care experts to discuss ways to "get ... promotes the health of all Americans through better prevention and management ...
... TAMPA, Fla., Sept. 16 If the troubled economy has ... for knowledge and hard work. Speculators can finagle a decent living ... often unemployment, bankruptcy and foreclosure when times get tough. Those who ... it will provide the kind of success that lasts a lifetime ...
... , , LOS ANGELES, Sept. 16 ... awarded LA,s Best Award (tm) 2009 for his leading edge, high ... work in cosmetic dentistry and bite reconstruction and has recently trademarked ... dental technologies to achieve a level of care that is beyond ...
... , , , ... Occupational HealthLink, Inc., today announced it has changed its business ... , "We are very excited about the ... Axion Health allows us to better represent our business as ...
... , MURRIETA, Calif., Sept. 16 ... provides drug and alcohol rehabilitation and a variety of other behavioral ... it has updated its web sites at www.forterushealthcare.com ... facility. , , "It is very important that ...
... ... Wake Forest, NC-based company that is recognized as the leading provider of care management ... ... 2009 -- Digital Healthcare, the Cambridge England and Wake Forest, NC based company that ...
Cached Medicine News:Health News:National Coalition Brings Together Experts to Evaluate Current Health Reform Proposals on Wellness, Disease Prevention Provisions 2Health News:Learn Your Way to Success 2Health News:Learn Your Way to Success 3Health News:Los Angeles Dentist Dr. Sam Muslin Receives LA's Best Award 2009 2Health News:Los Angeles Dentist Dr. Sam Muslin Receives LA's Best Award 2009 3Health News:Los Angeles Dentist Dr. Sam Muslin Receives LA's Best Award 2009 4Health News:Los Angeles Dentist Dr. Sam Muslin Receives LA's Best Award 2009 5Health News:Los Angeles Dentist Dr. Sam Muslin Receives LA's Best Award 2009 6Health News:Los Angeles Dentist Dr. Sam Muslin Receives LA's Best Award 2009 7Health News:Axion Health Inc. Issues Notification of Business Name Change 2Health News:Axion Health Inc. Issues Notification of Business Name Change 3Health News:Forterus Inc. Launches Updated, Improved Web Site 2Health News:Retasure and Digital Healthcare Celebrate 10 Year Anniversary 2